Blue Water Ventures International, Inc. announced that it has received $0.771 million in funding

Psycheceutical Bioscience, Inc. is a bioscience company. The Company is engaged in developing cutting-edge delivery technologies to support safe psychedelic pharmaceutical medicines. The Company's technology is intended to deliver compounds across the blood-brain barrier while bypassing the gastrointestinal (GI) tract and liver, eliminating hallucinogenic effects and vastly reducing exposure to drug toxicities and side effects. The Company's systematic delivery system is designed to use extremely small multi-layered compounds, called Janus particles, to deliver targeted doses of any psychedelic compound directly through the blood-brain barrier, thereby bypassing the liver and reducing toxicity and side effects. The Company's NeuroDirect topical delivery system is a non-systemic delivery technology designed to deliver neuro-active compounds directly into the nerve tissue through topical application at the back of the neck.